Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties.
benzalkonium chloride
glaucoma
goblet cells
ocular surface
polyquaternium-1
travoprost
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
07
03
2022
received:
20
12
2021
accepted:
18
04
2022
pubmed:
10
5
2022
medline:
12
10
2022
entrez:
9
5
2022
Statut:
ppublish
Résumé
To investigate the effect of polyquaternium-1 (PQ)-preserved and benzalkonium chloride (BAK)-preserved travoprost eye drops on viability of primary human conjunctival goblet cell (GC) cultures and on secretion of mucin and cytokines. Furthermore, to evaluate the physicochemical properties of the branded travoprost eye drop Travatan® and available generics. The effect of travoprost eye drops was evaluated on GC cultures. Cell viability was assessed through lactate dehydrogenase (LDH) and tetrazolium dye (MTT) colorimetric assays. Mucin secretion was evaluated by immunohistochemical staining. Secretion of interleukin (IL)-6 and IL-8 was measured using BD Cytometric Bead Arrays. pH, viscosity, droplet mass, osmolality and surface tension were measured for all included eye drops. In the LDH assay, BAK travoprost caused significant GC loss after 2 hrs of incubation compared to the control. PQ travoprost caused no GC loss at any time point. Both PQ- and BAK travoprost caused secretion of mucin to the cytoplasma. No difference in IL-6 and IL-8 secretion was identified compared to controls. The pH values for the generics were lower (pH 6.0) than the pH value for Travatan (pH 6.7; p < 0.0001). The viscosity was lowest for Travatan, while the mean droplet mass was higher for Travatan (35 mg) than the generics (28-30 mg; p ≤ 0.0318). The osmolality and surface tension did not differ between the eye drops investigated. BAK travoprost caused GC loss, indicating that PQ preservation may be preferable in treatment of glaucoma. Furthermore, physicochemical properties of branded and generic travoprost eye drops can not be assumed to be identical.
Identifiants
pubmed: 35527390
doi: 10.1111/aos.15163
pmc: PMC9790398
doi:
Substances chimiques
Antihypertensive Agents
0
Benzalkonium Compounds
0
Interleukin-6
0
Interleukin-8
0
Mucins
0
Ophthalmic Solutions
0
Preservatives, Pharmaceutical
0
Lactate Dehydrogenases
EC 1.1.-
Travoprost
WJ68R08KX9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
819-827Subventions
Organisme : Bagenkop Nielsen's Eye Foundation
Organisme : Fight for Sight (Denmark)
Organisme : the A.P MO;ller Foundation for Promotion of Medical Science
Organisme : the Danish Eye Research Foundation
Organisme : the Synoptik-foundation
Informations de copyright
© 2022 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Références
Br J Ophthalmol. 2021 Jun;105(Suppl 1):1-169
pubmed: 34675001
PLoS One. 2015 Jul 16;10(7):e0132048
pubmed: 26182236
Curr Eye Res. 2011 Nov;36(11):979-88
pubmed: 21999224
J Immunol. 2003 Mar 15;170(6):3369-76
pubmed: 12626597
Ophthalmic Res. 2012;48(2):89-101
pubmed: 22473057
Exp Eye Res. 2012 Jan;94(1):13-21
pubmed: 22067128
Ocul Surf. 2007 Apr;5(2):75-92
pubmed: 17508116
Ugeskr Laeger. 2017 Jan 30;179(5):
pubmed: 28397670
Prog Retin Eye Res. 2019 Jul;71:68-87
pubmed: 30471351
Acta Ophthalmol. 2017 Jun;95(4):370-373
pubmed: 28229536
J Ophthalmol. 2020 Jul 21;2020:6138132
pubmed: 32774906
Graefes Arch Clin Exp Ophthalmol. 1982;218(3):168-70
pubmed: 7095445
Clin Exp Ophthalmol. 2020 Sep;48(7):973-982
pubmed: 32564453
Curr Opin Allergy Clin Immunol. 2014 Oct;14(5):464-70
pubmed: 25061855
Am J Ophthalmol. 1997 Dec;124(6):723-8
pubmed: 9402817
Int Ophthalmol. 1991 Nov;15(6):371-6
pubmed: 1778667
Acta Ophthalmol. 2014 Aug;92(5):421-5
pubmed: 23837818
Turk J Ophthalmol. 2020 Apr 29;50(2):75-81
pubmed: 32366084
J Ocul Pharmacol Ther. 2019 May;35(4):223-228
pubmed: 30897019
J Glaucoma. 2019 Apr;28(4):325-333
pubmed: 30585937
Ocul Surf. 2006 Apr;4(2):62-73
pubmed: 16681077
Invest Ophthalmol Vis Sci. 2012 Aug 13;53(9):5443-50
pubmed: 22789923
J Glaucoma. 2008 Aug;17(5):350-5
pubmed: 18703943
Curr Eye Res. 1989 May;8(5):507-15
pubmed: 2736956
Am J Ophthalmol. 2015 Aug;160(2):266-274.e1
pubmed: 25935098
J Curr Glaucoma Pract. 2016 May-Aug;10(2):49-55
pubmed: 27536047
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
J Ocul Pharmacol Ther. 2014 Sep;30(7):548-53
pubmed: 24901262
Pathophysiology. 2017 Sep;24(3):123-131
pubmed: 28629694
Ophthalmology. 2019 Aug;126(8):1196-1198
pubmed: 30880107
Eur J Ophthalmol. 2012 Jan-Feb;22(1):34-44
pubmed: 22167541
Eur J Ophthalmol. 2007 May-Jun;17(3):341-9
pubmed: 17534814
Prog Retin Eye Res. 2016 Sep;54:49-63
pubmed: 27091323
Ocul Immunol Inflamm. 2011 Dec;19(6):401-12
pubmed: 22106907
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2406-2412
pubmed: 28444329
Rom J Ophthalmol. 2019 Jul-Sep;63(3):249-256
pubmed: 31687627
Biomed Hub. 2021 Aug 13;6(2):69-75
pubmed: 34616748